Curriculum Vitae Teun J. de Vries – April 2023.

---

1. Personalia

Name: Teunis (Teun) Johannes de Vries
Title: Dr. Ir.

Address work: Academic Centre for Dentistry
Amsterdam, Room 11N07
Gustav Mahlerlaan 3004
1081 LA Amsterdam
The Netherlands

2. Education

- Biology, MSC, specialization Cell Biology. Agricultural Univeristy Wageningen 1985-1991
- Post-Academic:
    - Laboratory animal science : "artikel 9 functionaris" - 1992
    - Leadership at academia - 2004
    - Certificate Primary Education for University teaching – 2012
    - Certificate on Mixed Classrooms - 2020
    - Certificate Senior Qualification for University teaching - 2021

3. Career

Ph.D. Student 1991-1995
Department of Pathology, Radboud University Nijmegen, The Netherlands.
Title thesis: The plasminogen activation system in melanocytic tumors. Date of ceremony 11th June 1996.

Post-doctoral researcher 1995-1999
Department of Pathology, Radboud University Nijmegen, The Netherlands.
Project of the Dutch Cancer Society. "Molecular detection of circulating melanoma cells".

Post- doctoral researcher 1999-2002
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University.
Project financed by Interdepartmental Research Institute IOT "Osteoclastogenesis".

Research fellow of the Royal Netherlands Academy of Sciences 2002-2007
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University.
"Cellular and nuclear diversity of osteoclasts"

Assistant professor 2007-2017
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University.

Associate professor 2017-
Department of Periodontology, Academic Centre for Dentistry Amsterdam (ACTA), University of Amsterdam and VU University.

Stays abroad

- Department of Anatomy, Medical School, Edinburgh University, Edinburgh, Scotland (June – December 1990)
- Fox Chase Cancer Center, Philadelphia, U.S.A. (October – December 1994)

4. Experience in teaching

4.1.1. Current teaching at ACTA

Teacher at Blok Gezonde mond – approximately 7 years
Lecture (= hoorcollege) gezonde mond
Lecture parodontium
Seminar (= werkcollege) I
Seminar II
Teacher at Blok Implantologie
Seminar
Teacher at Blok Groei en Ontwikkeling
Two lectures
Teacher at Blok Celbiologie
Seminar
Teacher at Oral Biology
Lecture
Teacher Immunology and Pathology
Coordinator

4.1.2. Current teaching at Mondzorgkunde INHOLLAND

Teacher Histologie van het parodontium
Two lectures
Seminar

4.1.3. Teaching at Amsterdam University college (AUC)

Molecular Cell Biology
Course coordinator
28 lectures a year
5 exams per student

Cell Biology and Physiology Lab
Course coordinator and teacher (a one month course)

4.1.4 Teaching at Research Master Human Movement Sciences

Molecular Cell Biology
Course coordinator
10 lectures
2x2 days practical

Exercise Immunology
2 lectures
Supervision of essay; second assessor essays.

4.2 Teaching committees

- **Project leader implementation of Team-Based Learning,** 2020-
- **Member on behalf of ACTA at Programme committee Human Movement Sciences** (Meets approximately 8 times per year, 2009-2017)
- **Member of Bachelor and Master internships ACTA on behalf of the department of Periodontology** (meets approximately 2 times a year – 2012-2020).
- **Member of the team dealing with Entry and choice dentistry sturdents** 2014-2019
- **Animal experiments officer on behalf of ACTA** – since 2010.
- **Member of Programme board ACTA** – 2017-2020.

5. Research managment

5.1.PhD supervisor: 11x finished.

Ton Schoenmaker: 21st September 2022Periodontal Ligament Fibroblasts as a cell biological tool in rare bone disease research. Lessons from Fibrodysplasia Ossificans Progressiva
Cindy Kelder: 7th July 2021: Towards 3D-Printed Bioactive Calcium Phosphate Scaffolds for Bone Tissue Engineering
Carolyn Moonen: (11th September 2019) Immunological aspects of the pathophysiology of periodontitis
Yixuan Cao: Osteoclast precursor in inflamed tissues 2014-2017
Sara Sprangers: Identification of molecular markers for a specific subset of osteoclasts in inflammation related bone pathologies 2014-2017
Bas ten Harkel: The foreign body giant cell. (Ph.D. defence: 26th January 2017)
Hessam Tabeian (2016, November 02). One temporomandibular joint, three different types of cartilage. The effect of inflammatory cytokines on the cartilages of the temporomandibular joint.
Jansen, I.D.C. (2015, March 09). Functional differences between site-specific osteoclasts.
Vermeer, A.F. (2014, October 21). Bone-site-specific responses to bisphosphonates. Long bone and jaw compared.
Scheres, N. (2011, June 10). Inflammatory responses of gingival and periodontal ligament fibroblasts to Porphyromonas gingivalis.
Bloemen, V. (2010, July 01). Cell-cell interactions during osteoclastogenesis.

5.2. Supervisor M.Sc. Periodontology

Rebecca Kirana: Periodontal ligament and alveolar bone mediated osteoclastogenesis and osteogenesis
Gerasimos Karlis: TLR2 and TLR4 activation and periodontal ligament associated osteogenesis and osteoclastogenesis
Stefano Andreotta: Plasminogen and periodontal ligament mediated osteogenesis and osteoclastogenesis. 2014.
Dimitris Sokos: Effect of infection with Porphyromonas gingivalis on periodontal ligament associated osteoclast formation. 2013.
Yossi Yousovich: Role of TNF-α in periodontal ligament fibroblast mediated osteoclast formation. 2012.
Azin Azari: Jaw and long bone marrow derived osteoclasts and their activity on dentin and long bone. 2011.
Stanley Tjoa: Osteoclastogenesis with PBMCs from periodontitis patients vs. controls. 2007.

5.3. Supervisor M.Sc. projects (last 10 years)

Karina Pigeaud, ACTA, 2022
Fatima Zamri, ACTA, 2019
Ibrahim Bakali, ACTA, 2018
Sebastiaan Moraal, ACTA, 2017
Fenne Wouters, Research Master Human Movement Sciences VU 2017
Jan Steinz, ACTA, 2016
Jeroen Langeveld, ACTA, 2014
Wiresh Bharos, ACTA, 2014
David Aerts, Molecular life sciences, University Utrecht, 2013

5.4. Supervisor B.Sc. projects (last 10 years)

Antonella Kleemann, AUC 2023
Caya Prins, AUC, 2023
Iris Leeuwrik and Pascale Kleinman, ACTA, 2023
Anna Wessels, AUC, 2022
Ruth Blakie, AUC, 2022
Amine Dahou Bouchankouk and Semih Özkan, ACTA 2021
Jade Pot and Sophie Jacobs, ACTA 2021
Victorine van der Cammen and Wiline van der Horst, ACTA 2021
Anna Spiering, AUC 2021
Hugo Ligthart, AUC 2021
Sophie Sutherland, AUC 2021
Aster Witvliet, AUC 2020
Melanie Rietveld, AUC 2020
Aukje Terpstra, AUC 2019
Kirsten Schut, AUC 2019
Lucy Tao, AUC 2019
Emily Schöningh, AUC 2019
Anne Strating, AUC 2019
Karen Yim, Amsterdam University College, 2018
Elizabete Ruppeka-Rupeika, Amsterdam Unversity College, 2017
Sven Aalders, Biomedical Sciences, VU, 2016
Simone Witte, Health and Life, VU, 2016
Doran Sol, ACTA, 2015
Siham Bouskla, Biomedical Sciences, VU, 2015
Tjardo Postma, Amsterdam University College, 2014
Marije te Winkel, Amsterdam Univeristy College, 2013

5.5. Role in projects

Euroclast (2013-2017): Work package leader resp. second work package leader.

Astrazeneca (+/- 2008): Co-principle investigator. Role AZD0530 in osteoclast fromation.

KNAW (2002-2007): Fellow, an own project that financed my salary and budget.

5.6. Awards

Bohn Stafleu Van Loghum/Thoden van Velzen Prize 2007 voor: De Vries TJ, Schoenmaker T, Wattanaroonwong N, van den HM, Nieuwenhuijse A, Beertsen W, Everts V. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts. J Cell Biochem 2006;98:370-82.

6. Scientific output

Statistics:

- Number: **124**
- Number of first authorships: **30**
- Number of last authorship: **30**
- Hirsch factor: **35** (on 28th April 2023)
- Average number of citations per article: **29,7**
- Sum IF: **815**
- Average IF/article: **6,6**
- Number of articles with IF > 10,0: **12.**
- Diverse areas: immunology, dentistry, cell biology, pathology, oncology, education.

1 The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts. Pigeaud KE, Rietveld ML, Witvliet AF, Hogervorst JMA, Zhang C, Forouzanfar T, Bravenboer N, Schoenmaker T, **de Vries TJ**. Int J Mol Sci. 2023 Apr 20;24(8):7574. doi: 10.3390/ijms24087574.

2. Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts.Schoenmaker T, Zwaak J, Loos BG, Volckmann R, Koster J, Eekhoff EMW, **de Vries TJ.** Int J Mol Sci. 2023 Apr 6;24(7):6822. doi: 10.3390/ijms24076822. PMID: 37047804

3. Mapping of DNA methylation-sensitive cellular processes in gingival and periodontal ligament fibroblasts in the context of periodontal tissue homeostasis. Lagosz-Cwik KB, Melnykova M, Nieboga E, Schuster A, Bysiek A, Dudek S, Lipska W, Kantorowicz M, Tyrakowski M, Darczuk D, Kaczmarzyk T, Gilijamse M, **de Vries TJ**, Potempa J, Grabiec AM. Front Immunol. 2023 Jan 26;14:1078031. doi: 10.3389/fimmu.2023.1078031. eCollection 2023. PMID: 36776856

4. A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts. Smilde BJ, Botman E, **de Vries TJ**, de Vries R, Micha D, Schoenmaker T, Janssen JJWM, Eekhoff EMW. Biomedicines. 2022 Nov 28;10(12):3063. doi: 10.3390/biomedicines10123063. PMID: 36551819

5. Editorial: Unveiling immunological mechanisms of periodontal diseases. **de Vries TJ**, de Souza PPC. Front Immunol. 2022 Nov 11;13:1081158. doi: 10.3389/fimmu.2022.1081158. eCollection 2022. PMID: 36439100
6. Real-time quantification of osteoclastic resorptive activity by electric cell-substrate impedance sensing. Jansen IDC, van Velzen T, **de Vries TJ**, Szulcek R, van Loon JJWA. Front Cell Dev Biol. 2022 Aug 19;10:921066. doi: 10.3389/fcell.2022.921066. eCollection 2022.PMID: 36060806

7. Intra-pulpal connective tissue formation and the advanced carious lesion: Is chondrogenesis and heterotopic ossification a response to pulpal inflammation? Demant S, Schoenmaker T, van Erck SMG, Dabelsteen S, **de Vries TJ**, Bjørndal L. Int Endod J. 2022 Nov;55(11):1212-1224. doi: 10.1111/iej.13821. Epub 2022 Sep 11. PMID: 36056458

8. Mechanisms of bone resorption. Everts V, Jansen IDC, **de Vries TJ**. Bone. 2022 Oct;163:116499. doi: 10.1016/j.bone.2022.116499. Epub 2022 Jul 21. PMID: 35872106

9. Editorial: Innovative Therapies in Bone Biology: What Can Be Learned From Rare Bone Diseases? Eekhoff EMW, **de Vries TJ**, Sakkers RJB, Van Hul W. Front Endocrinol (Lausanne). 2022 Jun 9;13:928667. doi:0.3389/fendo.2022.928667. eCollection 2022. PMID: 35757420

10. Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles. Eekhoff EMW, de Ruiter RD, Smilde BJ, Schoenmaker T, **de Vries TJ**, Netelenbos C, Hsiao EC, Scott C, Haga N, Grunwald Z, De Cunto CL, di Rocco M, Delai PLR, Diecidue RJ, Madhuri V, Cho TJ, Morhart R, Friedman CS, Zasloff M, Pals G, Shim JH, Gao G, Kaplan F, Pignolo RJ, Micha D. Hum Gene Ther. 2022 Aug;33(15-16):782-788. doi: 10.1089/hum.2022.023. PMID: 35502479

11.Editorial: Innovative Models in Bone Biology: What can be Learned from Rare Bone Diseases? **De Vries TJ**, Van Hul W, Eekhoff EMW. Front Endocrinol doi: 10.3389/fendo.2022.892799

12.Mutation in the CCAL1 locus accounts for bidirectional process of human subchondral bone turnover and cartilage mineralization. Rodríguez Ruiz A, van Hoolwerff M, Sprangers S, Suchiman E, Schoenmaker T, Dibbets-Schneider P, Bloem JL, Nelissen RGHH, Freund C, Mummery C, Everts V, **de Vries TJ**, Ramos YFM, Meulenbelt I. Rheumatology (Oxford). 2022 Apr 12:keac232. doi: 10.1093/rheumatology/keac232.

13.Limitations of Jaw Movement in Fibrodysplasia Ossificans Progressiva: A Review.

Schoenmaker T, Dahou Bouchankouk A, Özkan S, Gilijamse M, Bouvy-Berends E, Netelenbos C, Lobbezoo F, Eekhoff EMW, **de Vries TJ**.
Front Med (Lausanne). 2022 Mar 22;9:852678. doi: 10.3389/fmed.2022.852678

14.Diabetes Medication Metformin Inhibits Osteoclast Formation and Activity in In Vitro Models for Periodontitis.
Tao LY, Łagosz-Ćwik KB, Hogervorst JMA, Schoenmaker T, Grabiec AM, Forouzanfar T, van der Weijden FA, **de Vries TJ**.
Front Cell Dev Biol. 2022 Jan 13;9:777450. doi: 10.3389/fcell.2021.777450.

15.[Periodontitis - infection or inflammation?].
Laine ML, Rijkschroeff P, **de Vries TJ**, Zaura E.
Ned Tijdschr Tandheelkd. 2021 Dec;128(12):599-603. doi: 10.5177/ntvt.2021.12.21109

16.Why Females Do Better: The X Chromosomal TLR7 Gene-Dose Effect in COVID-19. Spiering AE, **de Vries TJ**. Front Immunol. 2021 Nov 11;12:756262. doi: 10.3389/fimmu.2021.756262.

17.Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop.
de Ruiter RD, Smilde BJ, Pals G, Bravenboer N, Knaus P, Schoenmaker T, Botman E, Sánchez-Duffhues G, Pacifici M, Pignolo RJ, Shore EM, van Egmond M, Van Oosterwyck H, Kaplan FS, Hsiao EC, Yu PB, Bocciardi R, De Cunto CL, Longo Ribeiro Delai P, **de Vries TJ**, Hilderbrandt S, Jaspers RT, Keen R, Koolwijk P, Morhart R, Netelenbos JC, Rustemeyer T, Scott C, Stockklausner C, Ten Dijke P, Triffit J, Ventura F, Ravazzolo R, Micha D, Eekhoff EMW.
Front Endocrinol (Lausanne). 2021 Nov 10;12:732728. doi: 10.3389/fendo.2021.732728.

18.Although anatomically micrometers apart: human periodontal ligament cells are slightly more active in bone remodeling than alveolar bone derived cells.
Loo-Kirana R, Gilijamse M, Hogervorst J, Schoenmaker T, **de Vries TJ**.
Front. Cell Devel. Biol.2021 Aug, doi: 10.3389/fcell.2021.709408

19.IgA Immune Complexes Induce Osteoclast-Mediated Bone Resorption.
Breedveld AC, van Gool MMJ, van Delft MAM, van der Laken CJ, **de Vries TJ**, Jansen IDC, van Egmond M.
Front Immunol. 2021 Jul 1;12:651049. doi: 10.3389/fimmu.2021.651049.

20.Activin-A Induces Early Differential Gene Expression Exclusively in Periodontal Ligament Fibroblasts from Fibrodysplasia Ossificans Progressiva Patients.
Schoenmaker T, Mokry M, Micha D, Netelenbos C, Bravenboer N, Gilijamse M, Eekhoff EMW, **de Vries TJ**.
Biomedicines. 2021 Jun 1;9(6):629. doi: 10.3390/biomedicines9060629.

21.The pandemic that has forced teachers to go online. Zooming in on tips for online teaching.
de Vries TJ
Front. Education 2021 doi: 10.3389/feduc.2021.647445

22.Increased Bone Resorption during Lactation in Pycnodysostosis.
Jansen IDC, Papapoulos SE, Bravenboer N, **de Vries TJ**, Appelman-Dijkstra NM.
Int J Mol Sci. 2021 Feb 11;22(4):1810. doi: 10.3390/ijms22041810.

23.Gingival epithelium attachment to well- or partially cured resin composites.
Boloori E, Schoenmaker T, Kleverlaan CJ, Loos BG, **de Vries TJ**.
Eur Cell Mater. 2020 Nov 26;40:259-275. doi: 10.22203/eCM.v040a16.

24.Use of TNF Inhibitors in Rheumatoid Arthritis and Implications for the Periodontal Status: For the Benefit of Both?
Zamri F, **de Vries TJ**.
Front Immunol. 2020 Oct 23;11:591365. doi: 10.3389/fimmu.2020.591365.

25.LAMP-2 Is Involved in Surface Expression of RANKL of Osteoblasts In Vitro.
Jansen IDC, Tigchelaar-Gutter W, Hogervorst JMA, **de Vries TJ**, Saftig P, Everts V.
Int J Mol Sci. 2020 Aug 25;21(17):6110. doi: 10.3390/ijms21176110.

26.Collaboration Around Rare Bone Diseases Leads to the Unique Organizational Incentive of the Amsterdam Bone Center.
Eekhoff EMW, Micha D, Forouzanfar T, **de Vries TJ**, Netelenbos JC,…., Koolwijk P, Janssen JJWM, Kloen P, Bravenboer N, Smit JM, Helder MN.
Front Endocrinol (Lausanne). 2020 Aug 11;11:481. doi: 10.3389/fendo.2020.00481.

27.Chronic Exposure of Gingival Fibroblasts to TLR2 or TLR4 Agonist Inhibits Osteoclastogenesis but Does Not Affect Osteogenesis.
Karlis GD, Schöningh E, Jansen IDC, Schoenmaker T, Hogervorst JMA, van Veen HA, Moonen CGJ, Łagosz-Ćwik KB, Forouzanfar T, **de Vries TJ**.
Front Immunol. 2020 Jul 23;11:1693. doi: 10.3389/fimmu.2020.01693.

28.Activin-A Induces Fewer, but Larger Osteoclasts From Monocytes in Both Healthy Controls and Fibrodysplasia Ossificans Progressiva Patients.
Schoenmaker T, Botman E, Sariyildiz M, Micha D, Netelenbos C, Bravenboer N, Kelder A, Eekhoff EMW, **De Vries TJ**.
Front Endocrinol (Lausanne). 2020 Jul 14;11:501. doi: 10.3389/fendo.2020.00501.

29.Tailored Teaching for Specialized (Para-)medical Students - Experience From Incorporating a Relevant Genetic Disease Throughout a Course of Molecular Cell Biology.
Schoenmaker T, Deng D, **de Vries TJ**.

Front Public Health. 2020 Jul 9;8:224. doi: 10.3389/fpubh.2020.00224.

30.Cells Derived from Human Long Bone Appear More Differentiated and More Actively Stimulate Osteoclastogenesis Compared to Alveolar Bone-Derived Cells.
Kelder C, Kleverlaan CJ, Gilijamse M, Bakker AD, **de Vries TJ**.
Int J Mol Sci. 2020 Jul 17;21(14):5072. doi: 10.3390/ijms21145072.

31.Increase in the Number of Bone Marrow Osteoclast Precursors at Different Skeletal Sites, Particularly in Long Bone and Jaw Marrow in Mice Lacking IL-1RA.
Ascone G, Cao Y, Jansen IDC, Di Ceglie I, van den Bosch MHJ, Blom AB, van Lent PLEM, Everts V, de Vries TJ.
Int J Mol Sci. 2020 May 27;21(11):3774. doi: 10.3390/ijms21113774.

32.Burst, Short, and Sustained Vitamin D3 Applications Differentially Affect Osteogenic Differentiation of Human Adipose Stem Cells.
Kelder C, Hogervorst JMA, Wismeijer D, Kleverlaan CJ, **de Vries TJ**, Bakker AD.
Int J Mol Sci. 2020 Apr 30;21(9):3202. doi: 10.3390/ijms21093202.

33. T Cell Proliferation Is Induced by Chronically TLR2-Stimulated Gingival Fibroblasts or Monocytes.
Moonen CGJ, Karlis GD, Schoenmaker T, Forouzanfar T, Loos BG, **de Vries TJ**.
Int J Mol Sci. 2019 Dec 5;20(24).

34. Editorial: Advances in Osteoimmunology.
Blin-Wakkach C, **de Vries TJ**.
Front Immunol. 2019 Nov 13;10:2595. doi: 10.3389/fimmu.2019.02595.

35. Effects of L-PRF and A-PRF+ on periodontal fibroblasts in in vitro wound healing experiments.
Pitzurra L, Jansen IDC, **de Vries TJ**, Hoogenkamp MA, Loos BG.
J Periodontal Res. 2019 Nov 28. doi: 10.1111/jre.12714. [Epub ahead of print]

36. Generation of Fibrodysplasia ossificans progressiva and control integration free iPSC lines from **periodontal** ligament fibroblasts.
Sanchez-Duffhues G, Mikkers H, de Jong D, Szuhai K, **de Vries TJ**, Freund C, Bravenboer N, van Es RJJ, Netelenbos JC, Goumans MJ, Eekhoff EMW, Ten Dijke P. Stem Cell Res. 2019 Dec;41:101639.

37.The Possible Role of Neutrophils in the Induction of Osteoclastogenesis.
Moonen CGJ, **de Vries TJ**, Rijkschroeff P, Poubelle PE, Nicu EA, Loos BG.
J Immunol Res. 2019 Sep 15;2019:8672604. doi: 10.1155/2019/8672604. eCollection 2019.

38. The Challenge of Teaching Essential Immunology Laboratory Skills to Undergraduates in One Month-Experience of an Osteoimmunology Course on TLR Activation.

de Vries TJ, Schoenmaker T, van Veen HA, Hogervorst J, Krawczyk PM, Moonen CGJ, Jansen IDC.
Front Immunol. 2019 Jul 31;10:1822.

39. Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions.
Madel MB, Ibáñez L, Wakkach A, **de Vries TJ**, Teti A, Apparailly F, Blin-Wakkach C.
Front Immunol. 2019 Jun 19;10:1408.

40. IL-1β Damages Fibrocartilage and Upregulates MMP-13 Expression in Fibrochondrocytes in the Condyle of the Temporomandibular Joint.
Tabeian H, Betti BF, Dos Santos Cirqueira C, **de Vries TJ**, Lobbezoo F, Ter Linde AV, Zandieh-Doulabi B, Koenders MI, Everts V, Bakker AD.
Int J Mol Sci. 2019 May 7;20(9).

41. What Are the Peripheral Blood Determinants for Increased Osteoclast Formation in the Various Inflammatory Diseases Associated With Bone Loss?
de Vries TJ, El Bakkali I, Kamradt T, Schett G, Jansen IDC, D'Amelio P.
Front Immunol. 2019 Mar 19;10:505.

42. The Osteocyte as a Novel Key Player in Understanding Periodontitis Through its Expression of RANKL and Sclerostin: a Review.
de Vries TJ, Huesa C.
Curr Osteoporos Rep. 2019 Jun;17(3):116-121.

43. Evolution of heterotopic bone in fibrodysplasia ossificans progressiva: An [18F]NaF PET/CT study.
Botman E, Raijmakers PGHM, Yaqub M, Teunissen B, Netelenbos C, Lubbers W, Schwarte LA, Micha D, Bravenboer N, Schoenmaker T, **de Vries TJ**, Pals G, Smit JM, Koolwijk P, Trotter DG, Lammertsma AA, Eekhoff EMW.
Bone. 2019 Jul;124:1-6.

44. The effect of Activin-A on periodontal ligament fibroblasts-mediated osteoclast formation in healthy donors and in patients with fibrodysplasia ossificans progressiva.
Schoenmaker T, Wouters F, Micha D, Forouzanfar T, Netelenbos C, Eekhoff EMW, Bravenboer N, **de Vries TJ**.
J Cell Physiol. 2019 Jul;234(7):10238-10247.

45. Hypoxia negatively affects senescence in osteoclasts and delays osteoclastogenesis.
Gorissen B, de Bruin A, Miranda-Bedate A, Korthagen N, Wolschrijn C, **de Vries TJ**, van Weeren R, Tryfonidou MA.
J Cell Physiol. 2018 Jan;234(1):414-426.

46. Survival, Retention, and Selective Proliferation of Lymphocytes Is Mediated by Gingival Fibroblasts.
Moonen CGJ, Alders ST, Bontkes HJ, Schoenmaker T, Nicu EA, Loos BG, **de Vries TJ.**
Front Immunol. 2018 Jul 25;9:1725.

47.Osteogenic and osteoclastogenic potential of jaw bone-derived cells - a case study.
Ruppeka-Rupeika E, Hogervorst J, Wouters F, Schoenmaker T, Forouzanfar T, **de Vries TJ**.
J Cell Biochem. 2018 Jan 24. doi: 10.1002/jcb.26690.

48. Periodontal ligament fibroblasts as a cell model to study osteogenesis and osteoclastogenesis in fibrodysplasia ossificans progressiva**.**
de Vries TJ, Schoenmaker T, Micha D, Hogervorst J, Bouskla S, Forouzanfar T, Pals G, Netelenbos C, Eekhoff EMW, Bravenboer N.
Bone. 2018; 109: 168-177.

49. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
Eekhoff EMW, Botman E, Coen Netelenbos J, de Graaf P, Bravenboer N, Micha D, Pals G, **de Vries TJ**, Schoenmaker T, Hoebink M, Lammertsma AA, Raijmakers PGHM. Bone. 2018; 109: 143-146.

50. Genes Critical for Developing Periodontitis: Lessons from Mouse Models.
de Vries TJ, Andreotta S, Loos BG, Nicu EA.
Front Immunol. 2017 Oct 27;8:1395. doi: 10.3389/fimmu.2017.01395. eCollection 2017. Review.

51. Influence of various air-abrasive powders on the viability and density of periodontal cells: An in vitro study.
Sygkounas E, Louropoulou A, Schoenmaker T, **de Vries TJ**, Van der Weijden FA.
J Biomed Mater Res B Appl Biomater. 2017 Sep 30.

52. TNF-α has both stimulatory and inhibitory effects on mouse monocyte-derived osteoclastogenesis.
Cao Y, Jansen IDC, Sprangers S, **de Vries TJ**, Everts V.
J Cell Physiol. 2017 Dec;232(12):3273-3285.

53.Genetic modification of ER-Hoxb8 osteoclast precursors using CRISPR/Cas9 as a novel way to allow studies on osteoclast biology.
Di Ceglie I, van den Akker GG, Ascone G, ten Harkel B, Häcker H, van de Loo FA, Koenders MI, van der Kraan PM, **de Vries TJ**, Vogl T, Roth J, van Lent PL. J. Leukocyte Biol. 2017 Apr;101(4):957-966.

54. Integrin αMβ2 is differently expressed by subsets of human osteoclast precursors and mediates adhesion of classical monocytes to bone.

Sprangers S, Schoenmaker T, Cao Y, Everts V, **de Vries TJ**.
Exp Cell Res. 2016 Nov 23. pii: S0014-4827(16)30390-1.[Epub ahead of print]

55. Juvenile porcine temporomandibular joint: Three different cartilaginous structures?
Tabeian H, Bakker AD, **de Vries TJ**, Zandieh-Doulabi B, Lobbezoo F, Everts V.
Arch Oral Biol. 2016 Dec;72:211-218.

56. Bone-site-specific responses to zoledronic acid.
Vermeer J, Renders G, van Duin MA, Jansen I, Bakker LF, Kroon SA, **de Vries TJ**, Everts V.
Oral Dis. 2016 Oct 5. doi: 10.1111/odi.12587. [Epub ahead of print]

57. Cyclic Tensile Strain Reduces TNF-α Induced Expression of MMP-13 by Condylar Temporomandibular Joint Cells.
Tabeian H, Bakker AD, Betti BF, Lobbezoo F, Everts V, **de Vries TJ**.
J Cell Physiol. 2016 Sep 12. doi: 10.1002/jcp.25593. [Epub ahead of print]

58. Monocyte Heterogeneity: Consequences for Monocyte-Derived Immune Cells.
Sprangers S, **de Vries TJ**, Everts V.
J Immunol Res. 2016;2016:1475435. Review.

59. Antisense Sense in Osteoclasts.
de Vries TJ.
Am J Pathol. 2016 Sep;186(9):2248-50.

60. IL-1β differently stimulates proliferation and multinucleation of distinct mouse bone marrow osteoclast precursor subsets.
Cao Y, Jansen ID, Sprangers S, Stap J, Leenen PJ, Everts V, **de Vries TJ**.
J Leukoc Biol. 2016 Sep;100(3):513-23.

61. Osteoblasts of calvaria induce higher numbers of osteoclasts than osteoblasts from long bone.
Wan Q, Schoenmaker T, Jansen ID, Bian Z, **de Vries TJ**, Everts V.
Bone. 2016 May;86:10-21.

62. Different Blood-Borne Human Osteoclast Precursors Respond in Distinct Ways to IL-17A.
Sprangers S, Schoenmaker T, Cao Y, Everts V, **de Vries TJ**.
J Cell Physiol. 2016 Jun;231(6):1249-60.

63. The Foreign Body Giant Cell Cannot Resorb Bone, But Dissolves Hydroxyapatite Like Osteoclasts.
ten Harkel B, Schoenmaker T, Picavet DI, Davison NL, **de Vries TJ**, Everts V.
PLoS One. 2015 Oct 1;10(10):e0139564. doi: 10.1371/journal.pone.0139564.

64. Tumor necrosis factor-α antagonist infliximab inhibits osteoclast formation of peripheral blood mononuclear cells but does not affect periodontal ligament fibroblast-mediated osteoclast formation.
de Vries TJ, Yousovich J, Schoenmaker T, Scheres N, Everts V.
J Periodontal Res. 2016 Apr;51(2):186-95.

65. M-CSF priming of osteoclast precursors can cause osteoclastogenesis-insensitivity, which can be prevented and overcome on bone.
De Vries TJ, Schoenmaker T, Aerts D, Grevers LC, Souza PP, Nazmi K, van de Wiel M, Ylstra B, Lent PL, Leenen PJ, Everts V.
J Cell Physiol. 2015 Jan;230(1):210-25.

66. Role of periodontal ligament fibroblasts in osteoclastogenesis: a review.
Sokos D, Everts V, **de Vries TJ**.
J Periodontal Res. 2015 Apr;50(2):152-9.

67. A challenge with Porphyromonas gingivalis differentially affects the osteoclastogenesis potential of periodontal ligament fibroblasts from periodontitis patients and non-periodontitis donors.
Sokos D, Scheres N, Schoenmaker T, Everts V, **de Vries TJ**.
J Clin Periodontol. 2014 Feb;41(2):95-103.

68. Jaw bone marrow-derived osteoclast precursors internalize more bisphosphonate than long-bone marrow precursors.
Vermeer JA, Jansen ID, Marthi M, Coxon FP, McKenna CE, Sun S, **de Vries TJ**, Everts V.
Bone. 2013 Nov;57(1):242-51.

69. Osteoclast precursors in murine bone marrow express CD27 and are impeded in osteoclast development by CD70 on activated immune cells.
Xiao Y, Song JY, **de Vries TJ**, Fatmawati C, Parreira DB, Langenbach GE, Babala N, Nolte MA, Everts V, Borst J.
Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12385-90.

70. Magnesium deficiency results in an increased formation of osteoclasts.
Belluci MM, Schoenmaker T, Rossa-Junior C, Orrico SR, **de Vries TJ**, Everts V.
J Nutr Biochem. 2013 Aug;24(8):1488-98.

71. Immune complex-induced inhibition of osteoclastogenesis is mediated via activating but not inhibitory Fcγ receptors on myeloid precursor cells.
Grevers LC, **de Vries TJ**, Everts V, Verbeek JS, van den Berg WB, van Lent PL.
Ann Rheum Dis. 2013 Feb;72(2):278-85.

72. T cell-mediated increased osteoclast formation from peripheral blood as a mechanism for Crohn's disease-associated bone loss.
Oostlander AE, Everts V, Schoenmaker T, Bravenboer N, van Vliet SJ, van Bodegraven AA, Lips P, **de Vries TJ**.

J Cell Biochem. 2012 Jan;113(1):260-8.

73. The transient receptor potential channel TRPV6 is dynamically expressed in bone cells but is not crucial for bone mineralization in mice.
van der Eerden BC, Weissgerber P, Fratzl-Zelman N, Olausson J, Hoenderop JG, Schreuders-Koedam M, Eijken M, Roschger P, **de Vries TJ**, Chiba H, Klaushofer K, Flockerzi V, Bindels RJ, Freichel M, van Leeuwen JP.
J Cell Physiol. 2012 May;227(5):1951-9.

74. Jaw and long bone marrow derived osteoclasts differ in shape and their response to bone and dentin.
Azari A, Schoenmaker T, de Souza Faloni AP, Everts V, **de Vries TJ**.
Biochem Biophys Res Commun. 2011 Jun 3;409(2):205-10.

75. Diverse effects of Porphyromonas gingivalis on human osteoclast formation.
Scheres N, **de Vries TJ**, Brunner J, Crielaard W, Laine ML, Everts V.
Microb Pathog. 2011 Sep;51(3):149-55.

76. Osteoclast progenitors from cats with and without tooth resorption respond differently to 1,25-dihydroxyvitamin D and interleukin-6.
Booij-Vrieling HE, **de Vries TJ**, Schoenmaker T, Tryfonidou MA, Penning LC, Hazewinkel HA, Everts V.
Res Vet Sci. 2012 Apr;92(2):311-6.

77. IL-1β favors osteoclastogenesis via supporting human periodontal ligament fibroblasts.
Bloemen V, Schoenmaker T, **de Vries TJ**, Everts V.
J Cell Biochem. 2011 Jul;112(7):1890-7.

78. Intravenously delivered glucocorticoid liposomes inhibit osteoclast activity and bone erosion in murine antigen-induced arthritis.
Hofkens W, Grevers LC, Walgreen B, **de Vries TJ**, Leenen PJ, Everts V, Storm G, van den Berg WB, van Lent PL.
J Control Release. 2011 Jun 30;152(3):363-9.

79. S100A8 enhances osteoclastic bone resorption in vitro through activation of Toll-like receptor 4: implications for bone destruction in murine antigen-induced arthritis.
Grevers LC, **de Vries TJ**, Vogl T, Abdollahi-Roodsaz S, Sloetjes AW, Leenen PJ, Roth J, Everts V, van den Berg WB, van Lent PL.
Arthritis Rheum. 2011 May;63(5):1365-75.

80. Periodontal ligament and gingival fibroblasts from periodontitis patients are more active in interaction with Porphyromonas gingivalis.
Scheres N, Laine ML, Sipos PM, Bosch-Tijhof CJ, Crielaard W, **de Vries TJ**, Everts V.
J Periodontal Res. 2011 Aug;46(4):407-16.

81. Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts.
Wattanaroonwong N, Schoenmaker T, **de Vries TJ**, Everts V.
Arch Oral Biol. 2011 Mar;56(3):212-9.

82. Jaw and long bone marrows have a different osteoclastogenic potential.
de Souza Faloni AP, Schoenmaker T, Azari A, Katchburian E, Cerri PS, **de Vries TJ**, Everts V.
Calcif Tissue Int. 2011 Jan;88(1):63-74.

83. Nonablative neonatal bone marrow transplantation rapidly reverses severe murine osteopetrosis despite low-level engraftment and lack of selective expansion of the osteoclastic lineage.
Flores C, **de Vries TJ**, Moscatelli I, Askmyr M, Schoenmaker T, Langenbach GE, Ehinger M, Everts V, Richter J.
J Bone Miner Res. 2010 Sep;25(9):2069-77.

84. Direct cell-cell contact between periodontal ligament fibroblasts and osteoclast precursors synergistically increases the expression of genes related to osteoclastogenesis.
Bloemen V, Schoenmaker T, **de Vries TJ**, Everts V.
J Cell Physiol. 2010 Mar;222(3):565-73.

85. Gingival and periodontal ligament fibroblasts differ in their inflammatory response to viable Porphyromonas gingivalis.
Scheres N, Laine ML, **de Vries TJ**, Everts V, van Winkelhoff AJ.
J Periodontal Res. 2010 Apr;45(2):262-70.

86. Inhibitory regulation of osteoclast bone resorption by signal regulatory protein alpha.
van Beek EM, **de Vries TJ**, Mulder L, Schoenmaker T, Hoeben KA, Matozaki T, Langenbach GE, Kraal G, Everts V, van den Berg TK.
FASEB J. 2009 Dec;23(12):4081-90.

87. Ae2(a,b)-deficient mice exhibit osteopetrosis of long bones but not of calvaria.
Jansen ID, Mardones P, Lecanda F, **de Vries TJ**, Recalde S, Hoeben KA, Schoenmaker T, Ravesloot JH, van Borren MM, van Eijden TM, Bronckers AL, Kellokumpu S, Medina JF, Everts V, Oude Elferink RP.
FASEB J. 2009 Oct;23(10):3470-81.

88. Intercellular adhesion molecule-1 clusters during osteoclastogenesis.
Bloemen V, **de Vries TJ**, Schoenmaker T, Everts V.
Biochem Biophys Res Commun. 2009 Aug 7;385(4):640-5.

89. Osteoclast heterogeneity: lessons from osteopetrosis and inflammatory conditions.
Everts V, **de Vries TJ**, Helfrich MH.
Biochim Biophys Acta. 2009 Aug;1792(8):757-65.

90. Transcription factor C/EBPbeta isoform ratio regulates osteoclastogenesis through MafB.
Smink JJ, Bégay V, Schoenmaker T, Sterneck E, **de Vries TJ**, Leutz A.
EMBO J. 2009 Jun 17;28(12):1769-81.

91. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ, Mullender MG, van Duin MA, Semeins CM, James N, Green TP, Everts V, Klein-Nulend J.
Mol Cancer Res. 2009 Apr;7(4):476-88.

92. Vitamin B(12) deficiency stimulates osteoclastogenesis via increased homocysteine and methylmalonic acid.
Vaes BL, Lute C, Blom HJ, Bravenboer N, **de Vries TJ**, Everts V, Dhonukshe-Rutten RA, Müller M, de Groot LC, Steegenga WT.
Calcif Tissue Int. 2009 May;84(5):413-22.

93. Myeloid blasts are the mouse bone marrow cells prone to differentiate into osteoclasts.
de Vries TJ, Schoenmaker T, Hooibrink B, Leenen PJ, Everts V.
J Leukoc Biol. 2009 Jun;85(6):919-27.

94. **de Vries TJ**, Everts V. Osteoclast formation from peripheral blood of patients with bone-lytic diseases. Clinical Reviews in Bone and Mineral Metabolism, 7 (4), 285-292.

95. Formation of osteoclast-like cells from peripheral blood of periodontitis patients occurs without supplementation of macrophage colony-stimulating factor.
Tjoa ST, **de Vries TJ**, Schoenmaker T, Kelder A, Loos BG, Everts V.
J Clin Periodontol. 2008 Jul;35(7):568-75.

96. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia.
Olivier BJ, Schoenmaker T, Mebius RE, Everts V, Mulder CJ, van Nieuwkerk KM, **de Vries TJ**, van der Merwe SW.
Hepatology. 2008 Jan;47(1):259-67.

97. Osteocytes subjected to fluid flow inhibit osteoclast formation and bone resorption.
Tan SD, **de Vries TJ**, Kuijpers-Jagtman AM, Semeins CM, Everts V, Klein-Nulend J.

Bone. 2007 Nov;41(5):745-51.

98. Hematopoietic stem cell-targeted neonatal gene therapy reverses lethally progressive osteopetrosis in oc/oc mice.
Johansson MK, **de Vries TJ**, Schoenmaker T, Ehinger M, Brun AC, Fasth A, Karlsson S, Everts V, Richter J.
Blood. 2007 Jun 15;109(12):5178-85.

99. Fcgamma receptors directly mediate cartilage, but not bone, destruction in murine antigen-induced arthritis: uncoupling of cartilage damage from bone erosion and joint inflammation.
van Lent PL, Grevers L, Lubberts E, **de Vries TJ**, Nabbe KC, Verbeek S, Oppers B, Sloetjes A, Blom AB, van den Berg WB.
Arthritis Rheum. 2006 Dec;54(12):3868-77.

100. Gingival fibroblasts are better at inhibiting osteoclast formation than periodontal ligament fibroblasts.
de Vries TJ, Schoenmaker T, Wattanaroonwong N, van den Hoonaard M, Nieuwenhuijse A, Beertsen W, Everts V.
J Cell Biochem. 2006 May 15;98(2):370-82.

101. The epithelial Ca2+ channel TRPV5 is essential for proper osteoclastic bone resorption.
van der Eerden BC, Hoenderop JG, **de Vries TJ**, Schoenmaker T, Buurman CJ, Uitterlinden AG, Pols HA, Bindels RJ, van Leeuwen JP.
Proc Natl Acad Sci U S A. 2005 Nov 29;102(48):17507-12.

102. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation.
de Vries TJ, Schoenmaker T, Beertsen W, van der Neut R, Everts V.
J Cell Biochem. 2005 Apr 1;94(5):954-66.

103. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ, Smeets M, de Graaf R, Hou-Jensen K, Bröcker EB, Renard N, Eggermont AM, van Muijen GN, Ruiter DJ.
J Pathol. 2001 Jan;193(1):13-20.

104. Analysis of melanoma cells in peripheral blood by reverse transcription-polymerase chain reaction for tyrosinase and MART-1 after mononuclear cell collection with cell preparation tubes: a comparison with the whole blood guanidinium isothiocyanate RNA isolation method.
de Vries TJ, Fourkour A, Punt CJ, Ruiter DJ, van Muijen GN.
Melanoma Res. 2000 Apr;10(2):119-26.

105. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines.
dos Santos NR, Torensma R, **de Vries TJ**, Schreurs MW, de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van Muijen GN, van Kessel AG.
Cancer Res. 2000 Mar 15;60(6):1654-62.

106. Melanoma-inhibiting activity (MIA) mRNA is not exclusively transcribed in melanoma cells: low levels of MIA mRNA are present in various cell types and in peripheral blood.
de Vries TJ, Fourkour A, Punt CJ, Diepstra H, Ruiter DJ, van Muijen GN.
Br J Cancer. 1999 Nov;81(6):1066-70.

107. Transcription of the MAGE-1 gene and the methylation status of its Ets binding promoter elements: a quantitative analysis in melanoma cell lines using a real-time polymerase chain reaction technique.
Janssen BL, van de Locht LT, Fourkour A, de Smet C, Mensink EJ, van Muijen GN, **de Vries TJ**.
Melanoma Res. 1999 Jun;9(3):213-22.

108. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR.
de Vries TJ, Fourkour A, Punt CJ, van de Locht LT, Wobbes T, van den Bosch S, de Rooij MJ, Mensink EJ, Ruiter DJ, van Muijen GN.
Br J Cancer. 1999 May;80(5-6):883-91.

109. Reliability of reverse transcription-polymerase chain reaction (RT-PCR)-based assays for the detection of circulating tumour cells: a quality-assurance initiative of the EORTC Melanoma Cooperative Group.
Keilholz U, Willhauck M, Rimoldi D, Brasseur F, Dummer W, Rass K, **de Vries T**, Blaheta J, Voit C, Lethé B, Burchill S.
Eur J Cancer. 1998 Apr;34(5):750-3.

110. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
de Vries TJ, Trancikova D, Ruiter DJ, van Muijen GN.
Br J Cancer. 1998 Nov;78(9):1156-61.

111. Polymerase chain reaction detection of circulating tumour cells. EORTC Melanoma Cooperative Group, Immunotherapy Subgroup.
Keilholz U, Willhauck M, Scheibenbogen C, **de Vries TJ**, Burchill S.
Melanoma Res. 1997 Aug;7 Suppl 2:S133-41. Review.

112. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ, van Muijen GN.

Cancer Res. 1997 Aug 1;57(15):3223-9.

113. The plasminogen activation system in tumour invasion and metastasis.
de Vries TJ, van Muijen GN, Ruiter DJ.
Pathol Res Pract. 1996 Jul;192(7):718-33. Review.

114. Tetranectin and plasmin/plasminogen are similarly distributed at the invasive front of cutaneous melanoma lesions.
De Vries TJ, De Wit PE, Clemmensen I, Verspaget HW, Weidle UH, Bröcker EB, Ruiter DJ, Van Muijen GN.
J Pathol. 1996 Jul;179(3):260-5.

115. E-cadherin expression in human melanoma.
Danen EH, **de Vries TJ**, Morandini R, Ghanem GG, Ruiter DJ, van Muijen GN.
Melanoma Res. 1996 Apr;6(2):127-31.

116. The plasminogen activation system in melanoma cell lines and in melanocytic lesions.
de Vries TJ, van Muijen GN, Ruiter DJ.
Melanoma Res. 1996 Apr;6(2):79-88. Review.

117. Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions - a minireview.
De Vries TJ, Ruiter DJ, Weidle UH, Van Muijen GNP. Fibrinolysis 1996;10:91-4.

118. Decreased expression of both the low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor and its receptor-associated protein in late stages of cutaneous melanocytic tumor progression.
de Vries TJ, Verheijen JH, de Bart AC, Weidle UH, Ruiter DJ, van Muijen GN.
Cancer Res. 1996 Mar 15;56(6):1432-9.

119. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
de Vries TJ, Kitson JL, Silvers WK, Mintz B.
Cancer Res. 1995 Oct 15;55(20):4681-7.

120. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GN.
J Pathol. 1995 Jan;175(1):59-67.

121. Properties of metastasizing and nonmetastasizing human melanoma cells.
van Muijen GN, Danen EH, **de Vries TJ**, Quax PH, Verheijen JH, Ruiter DJ.
Recent Results Cancer Res. 1995;139:105-22. Review.

122. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression.
de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN.
Am J Pathol. 1994 Jan;144(1):70-81.

123. Studies on functional and structural role of urokinase receptor and other components of the plasminogen activation system in malignancy.
Weidle UH, Wöllisch E, Rønne E, Ploug M, Behrendt N, **de Vries TJ**, Quax PH, Verheijen JH, van Muijen GN, Ruiter DJ, et al.
Ann Biol Clin (Paris). 1994;52(11):775-82.

124. The differential staining pattern of the X chromosome in the embryonic and extraembryonic tissues of postimplantation homozygous tetraploid mouse embryos.
Webb S, **de Vries TJ**, Kaufman MH.Genet Res. 1992 Jun;59(3):205-14.

Signed by Teunis Johannes de Vries, in Amsterdam on 28th of April 2023